Philip Lazarovici Selected Research

trkA Receptor

1/2007	The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma.
1/2004	Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.
10/2003	Establishment and characterization of pheochromocytoma tumor models expressing different levels of trkA receptors.
6/2003	Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip Lazarovici Research Topics

Disease

29	Neoplasms (Cancer) 12/2020 - 08/2002
12	Ischemia 12/2020 - 01/2002
12	Pheochromocytoma 02/2018 - 01/2002
7	Glioma (Gliomas) 06/2015 - 12/2008
6	Stroke (Strokes) 12/2020 - 08/2005
6	Carcinoma (Carcinomatosis) 07/2013 - 01/2003
4	Nervous System Diseases (Neurological Disorders) 01/2022 - 01/2017
4	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2022 - 06/2011
4	Wounds and Injuries (Trauma) 01/2018 - 06/2010
4	Melanoma (Melanoma, Malignant) 10/2012 - 09/2004
3	Ischemic Stroke 01/2022 - 08/2005
3	Lung Diseases (Lung Disease) 01/2021 - 09/2015
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 04/2007
3	Pain (Aches) 05/2019 - 07/2015
3	Brain Ischemia (Cerebral Ischemia) 01/2019 - 11/2012
3	Reperfusion Injury 01/2019 - 01/2013
3	Schizophrenia (Dementia Praecox) 01/2018 - 08/2017
3	Parkinson Disease (Parkinson's Disease) 06/2007 - 01/2004
2	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2022
2	Myocardial Infarction 12/2020 - 01/2013
2	Malaria 10/2019 - 01/2016
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2019 - 11/2012
2	Glioblastoma (Glioblastoma Multiforme) 06/2018 - 12/2008
2	Arthritis (Polyarthritis) 09/2015 - 01/2006
2	Pathologic Neovascularization 09/2013 - 07/2012
2	Colorectal Neoplasms (Colorectal Cancer) 07/2013 - 01/2012
2	Neoplasm Metastasis (Metastasis) 03/2013 - 08/2009
2	Infarction (Infarctions) 01/2013 - 06/2011
2	Breast Neoplasms (Breast Cancer) 10/2012 - 01/2004
2	Hypoxia (Hypoxemia) 12/2011 - 01/2011
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2006 - 01/2004
1	COVID-19 01/2022
1	Cytokine Release Syndrome 01/2022
1	Virus Diseases (Viral Diseases) 01/2022
1	Epilepsy (Aura) 01/2022
1	Multiple Sclerosis 12/2021
1	Autoimmune Diseases (Autoimmune Disease) 12/2021
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 12/2021
1	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2021
1	Cardiotoxicity 12/2020

Drug/Important Bio-Agent (IBA)

25	Nerve Growth Factor (NGF)IBA 05/2019 - 01/2002
12	Neuroprotective AgentsIBA 01/2022 - 05/2002
10	Pharmaceutical PreparationsIBA 12/2020 - 11/2006
10	Proteins (Proteins, Gene)FDA Link 10/2019 - 06/2003
9	IntegrinsIBA 12/2021 - 12/2008
7	Oxygen (Dioxygen)IBA 12/2020 - 01/2002
6	Nerve Growth Factors (Neurotrophins)IBA 01/2021 - 10/2003
6	Glucose (Dextrose)FDA LinkGeneric 12/2020 - 01/2002
6	CollagenIBA 05/2013 - 03/2009
6	Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)IBA 06/2010 - 06/2003
5	Dopamine (Intropin)FDA LinkGeneric 01/2018 - 10/2003
5	Phosphotransferases (Kinase)IBA 01/2013 - 01/2003
4	Peptides (Polypeptides)IBA 12/2020 - 09/2010
4	DisintegrinsIBA 09/2020 - 12/2008
4	Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA 01/2018 - 01/2004
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2015 - 08/2005
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2015 - 06/2003
4	trkA ReceptorIBA 01/2007 - 06/2003
4	Mitogen-Activated Protein KinasesIBA 01/2007 - 01/2003
4	JNK Mitogen-Activated Protein KinasesIBA 01/2007 - 01/2003
3	Snake Venoms (Snake Venom)IBA 01/2020 - 10/2003
3	tuftelin (enamelin)IBA 05/2019 - 01/2011
3	Biological ProductsIBA 05/2019 - 05/2004
3	ErbB Receptors (EGF Receptor)IBA 06/2018 - 01/2012
3	Messenger RNA (mRNA)IBA 09/2017 - 06/2003
3	Monoamine Oxidase (MAO)IBA 06/2007 - 01/2002
3	Glycerol (Glycerine)FDA LinkGeneric 01/2007 - 01/2003
2	Glutamic Acid (Glutamate)FDA Link 01/2022 - 08/2017
2	CytokinesIBA 01/2022 - 02/2015
2	Cyclic PeptidesIBA 12/2021 - 09/2020
2	Monoclonal AntibodiesIBA 12/2021 - 01/2012
2	Collagen ReceptorsIBA 09/2020 - 08/2009
2	VenomsIBA 01/2020 - 03/2017
2	artemisinin (artemisinine)IBA 10/2019 - 01/2016
2	CalciumIBA 02/2018 - 06/2002
2	staurosporine aglycone (K252a)IBA 01/2018 - 06/2010
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2018 - 08/2017
2	Antipsychotic Agents (Antipsychotics)IBA 01/2018 - 08/2017
2	tempolIBA 10/2016 - 11/2006
2	AntibodiesIBA 08/2014 - 09/2013
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 09/2013 - 09/2006
2	Epidermal Growth Factor (EGF)IBA 07/2013 - 01/2012
2	rasagiline (Azilect)FDA Link 06/2007 - 01/2002
2	homocarnosineIBA 02/2004 - 05/2002
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2022
1	Therapeutic UsesIBA 12/2021
1	Natalizumab (Tysabri)FDA Link 12/2021
1	AcidsIBA 12/2020
1	humaninIBA 12/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2020
1	arginyl-glycyl-aspartic acidIBA 09/2020
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 09/2020
1	Coloring Agents (Dyes)IBA 09/2020
1	CorticosteroneIBA 01/2020
1	Sucrose (Saccharose)IBA 01/2020

Therapy/Procedure

23	Therapeutics 01/2022 - 08/2005
5	Transplantation 02/2018 - 06/2011
3	Cell- and Tissue-Based Therapy (Cell Therapy) 02/2018 - 03/2009
2	Drug Therapy (Chemotherapy) 09/2017 - 10/2003
1	Immunotherapy 12/2021